Patent ID: 9134310
Filing Date: 2015-09-15
Classification: A61K,A61P,C07K,G01N

Abstract:
1. An in vitro method of identifying a compound useful to activate or suppress anti-inflammatory activity associated with IgG autoantibody-mediated inflammation, which comprises: (a) exposing DC-SIGN (b) measuring the increase or decrease in a cellular component within the DC-SIGN (c) selecting the test compound as useful (i) to activate the anti-inflammatory activity associated with IgG autoantibody-mediated inflammation if the compound is an agonist of the receptor protein and causes a measureable increase of the cellular component, or (ii) to suppress the anti-inflammatory activity associated with IgG autoantibody-mediated inflammation if the compound is an antagonist or inverse agonist of the receptor protein and causes a measureable decrease of the cellular component; thereby identifying the compound as useful to activate or suppress anti-inflammatory activity associated with IgG autoantibody-mediated inflammation, wherein the cellular component is selected from the group consisting of Erk1, Erk2, PI3K, IL-10, intracellular calcium, ATF3, MHC II, a MHC II component, Jagged 1, and interferon-response transcripts.